K. Guito

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

S. Hoffman, D. Kaslow, R. Anders, 1998, The Journal of infectious diseases.

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

J. Schlom, H. Kaufman, J. Tine, 2000, Cancer Immunology, Immunotherapy.

Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine in infants.

E. Rothstein, K. Reisinger, H. Bernstein, 1993, American journal of diseases of children.

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria

E. Paoletti, S. Hoffman, D. Smith, 1996, Infection and immunity.